Assist Prof Dr. Farzad Nasiri | Clinical Psychology| Best Researcher Award

 Assist Prof Dr. Farzad Nasiri | Clinical Psychology | Best Researcher Award  🏆

University of Kurdistan,IRAN 🎓

Dr. Farzad Nasiri is an Associate Professor at the University of Kurdistan, where he also serves as the Head of the Department of Psychology. With a rich background in clinical and experimental psychology, he has been dedicated to advancing both academic research and therapeutic practice. His professional journey is marked by a strong commitment to psychology and cognitive-behavioral therapy (CBT), particularly in the treatment of anxiety and mood disorders.

 

 

Professional Profile 

🎓 Education

Dr. Nasiri completed his Ph.D. in Psychology in 2019 at Ferdowsi University of Mashhad, following his Master’s (2012) and Bachelor’s degrees (2010) in Clinical Psychology from the University of Tabriz. His academic journey began with a High School Diploma in Experimental Sciences from Shaheed Beheshti School in 2004, highlighting his early dedication to scientific disciplines.

 

🏢 Work Experience

Dr. Nasiri has extensive experience as a university professor, teaching Ph.D., Master’s, and Bachelor’s courses in clinical psychology, cognitive psychology, neuropsychology, and psychotherapy techniques. In addition to his academic roles, he has been a reviewer and editor for various scientific journals, including the Journal of Clinical Psychology and Counseling and the Journal of Medical Sciences.

 

🧬 Skills

Dr. Nasiri’s expertise lies in Cognitive Behavioral Therapy (CBT) and transcranial direct current stimulation (tDCS). He has led workshops on anxiety management and tDCS, and his therapeutic focus centers on mood and anxiety disorders. His extensive research covers mindfulness-based therapies, emotional regulation, and executive functions in psychological disorders.

Awards and Honors 🏆

Throughout his career, Dr. Nasiri has earned exceptional grades, with notable recognition for his research and clinical work. His thesis projects earned the highest distinctions, including a perfect score of 20 for his Ph.D. dissertation under Dr. Ali Mashhadi.

 

🔬 Research Focus

Dr. Nasiri’s research spans cognitive and emotional indices of anxiety, transdiagnostic therapy, and mindfulness-based interventions. He has authored several books and translated works on CBT, chronic pain, insomnia, and autism. His scholarly publications address critical psychological issues, including anxiety disorders, resilience, and emotional regulation strategies.

 

📚 Publilcation 

  • Comparison of executive functions in people with high and low resilience
    Year: 2024 | Journal: Journal of Psychiatric Research
    (Shariati, A., Nasiri, F., Rahmani, F.)
  • A culturally adapted unified protocol for transdiagnostic treatment of anxiety disorders in adolescents (UP-A): A randomized waitlist-controlled trial
    Year: 2024 | Journal: Psychological Medicine
    (Zemestani, M., Ezzati, S., Nasiri, F., Barlow, D.H., Kendall, P.C.)
  • Augmenting the unified protocol with transcranial direct current stimulation: Effects on emotion regulation and executive dysfunction
    Year: 2023 | Journal: Clinical Psychology and Psychotherapy
    (Nasiri, F., Ellard, K.K., Mashhadi, A., Bigdeli, I., Ghanaei-Chamanabad, A.)
  • Premenstrual Syndrome: The Role of Emotion Regulation Strategies and Trait Meta-Mood
    Year: 2022 | Journal: Journal of Rational – Emotive and Cognitive – Behavior Therapy
    (Nasiri, F., Sharifi, S., Mashhadi, A., Sharp, R.)
  • How to Differentiate Generalized Anxiety Disorder from Worry: The Role of Cognitive Strategies
    Year: 2020 | Journal: Journal of Rational – Emotive and Cognitive – Behavior Therapy
    (Nasiri, F., Mashhadi, A., Bigdeli, I., Chamanabad, A.G.)
  • Augmenting the unified protocol for transdiagnostic treatment of emotional disorders with transcranial direct current stimulation in individuals with generalized anxiety disorder and comorbid depression: A randomized controlled trial
    Year: 2020 | Journal: Journal of Affective Disorders
    (Nasiri, F., Mashhadi, A., Bigdeli, I., Chamanabad, A.G., Ellard, K.K.)

 

 

Davide Arillotta | Mental health | Best Researcher Award

Dr Davide Arillotta | Mental health | Best Researcher Award 

Resident doctor at University of Florence; University of Hertfordshire,Italy

Davide Arillotta, MD, is a dynamic psychiatrist from Torino, Italy, with a strong passion for life sciences and mental health. Throughout his career, Dr. Arillotta has focused on substance use disorders, clinical toxicology, and the intersection of mental health and addiction. His work spans across clinical settings, research, and harm reduction initiatives, making significant contributions to both local and international communities.

professional profile 

scopus

 

🎓 Education

Dr. Arillotta holds a Master’s Degree in Medicine and Surgery (2014) from the University of Turin, Italy, where he also completed his psychiatric residency (2015-2019) at the University of Catania. He is currently enrolled in a Master’s programme in Cognitive Psychotherapy at Centro Clinico Crocetta, Turin. His academic journey includes several international experiences, including studies in Coimbra, Portugal, and research placements in the UK.

💼 Work Experience

Dr. Arillotta has served as a Clinical Toxicology Resident at the University of Florence since November 2021. He has extensive experience as a psychiatrist with various institutions, including NHS Trusts in Italy. He also worked as a freelance psychiatrist and collaborated on harm reduction projects in leisure environments. His clinical work spans general psychiatry, dual diagnosis, and substance use disorders.

🧠 Skills

 Dr. Arillotta possesses expertise in clinical toxicology, psychiatric care, and cognitive psychotherapy. He is skilled in the application of harm reduction strategies, tapering/switching protocols for chronic pain, and has significant experience in research and clinical trials related to novel psychoactive substances.

🏆 Awards and Honors

 Dr. Arillotta has been recognized for his outstanding contributions, winning the poster competition at the “New Challenges in Psychiatry” conference in Rome (2019) and securing a scholarship for a development cooperation project in Burkina Faso (2015).

👥 Memberships and Affiliations

He is affiliated with the Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit at the University of Hertfordshire, UK. Additionally, he was a delegate at the European Forum of Psychiatric Trainees (EFPT) in 2018.

📚 Teaching and Mentorship

Dr. Arillotta has contributed to the training of medical students and psychiatric trainees through workshops and scientific courses. His teaching is enhanced by his diverse clinical and research experiences, particularly in the fields of neuroethics and toxicology.

🔬 Research Focus

Dr. Arillotta’s research is centered on the psychopathological dimensions of substance abuse, biomarkers associated with cravings, and the adverse health effects of novel psychoactive substances like MDPHP. He is also exploring the potential impact of GLP-1 receptor agonists on mental health and addiction.

publication

  • “Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach”
    • 🗓 Year: 2024
    • 📜 Journal: Brain Sciences
    • 🔬 Topic: GLP-1 Receptor Agonists and their impact on substance use, compulsive behavior, and libido.
    • 🌐 Method: Mixed-Methods and Social Media Analysis
  • “Exploring the Association Between Suicidal Thoughts, Self-Injury, and GLP-1 Receptor Agonists in Weight Loss Treatments: Insights from Pharmacovigilance Measures and Unmasking Analysis”
    • 🗓 Year: 2024
    • 📜 Journal: European Neuropsychopharmacology
    • 🔬 Topic: Suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments.
    • 🚨 Focus: Pharmacovigilance and risk analysis
  • “Clinical Manifestations and Analytical Reports for MDPHP Acute Intoxication Cases”
    • 🗓 Year: 2024
    • 📜 Journal: Journal of Pharmaceutical and Biomedical Analysis
    • 🔬 Topic: MDPHP acute intoxication and clinical manifestations.
    • 💉 Focus: Toxicology and substance abuse
  • “Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions”
    • 🗓 Year: 2024
    • 📜 Journal: Scientia Pharmaceutica
    • 🔬 Topic: Semaglutide, calmodulin binding, and its effects on reward and behavior.
    • 🧠 Focus: Computational analysis and psychopharmacology
  • “GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach”
    • 🗓 Year: 2023
    • 📜 Journal: Brain Sciences
    • 🔬 Topic: Mental health effects of GLP-1 receptor agonists.
    • 🌐 Method: Social media and mixed-methods analysis
  • “Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?”
    • 🗓 Year: 2023
    • 📜 Journal: Pharmaceuticals
    • 🔬 Topic: Psilocybin as a treatment for depression.
    • 🍄 Focus: Psychedelics and mental health
  • “Covid-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis”
    • 🗓 Year: 2021
    • 📜 Journal: Brain Sciences
    • 🔬 Topic: Impact of Covid-19 on substance misuse.
    • 🦠 Focus: Social media analysis and substance use during the pandemic